2023
DOI: 10.1158/2767-9764.22546299.v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Supplementary Table TS1 from Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

Abstract: <p>Supplementary Table S1 shows EVT801 potency and selectivity profile</p>

Help me understand this report
View published versions

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles